Latest from The Ohio State University

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.
Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).
Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).
Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.
 
Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia. 
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.
Publication Bottom Border
Border Publication
x